{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:56:56Z","timestamp":1794484616605,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41584-026-01416-z","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:47:12Z","timestamp":1785844032000},"page":"605-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Navigating evidence-based recommendations for the management of systemic sclerosis"],"prefix":"10.1038","volume":"22","author":[{"given":"Francesco","family":"Del Galdo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-8310","authenticated-orcid":false,"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-2976","authenticated-orcid":false,"given":"Sindhu","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0053","authenticated-orcid":false,"given":"Voon H.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta A.","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-6569","authenticated-orcid":false,"given":"Elizabeth R.","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1416_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann, E. R., Andr\u00e9asson, K. & Smith, V. Systemic sclerosis. Lancet 401, 304\u2013318 (2023).","journal-title":"Lancet"},{"key":"1416_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo, F. et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann. Rheum. Dis. 84, 29\u201340 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR3","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","volume":"63","author":"CP Denton","year":"2024","unstructured":"Denton, C. P. et al. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology 63, 2956\u20132975 (2024).","journal-title":"Rheumatology"},{"key":"1416_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 76, 1182\u20131200 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1416_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","volume":"85","author":"KM Antoniou","year":"2026","unstructured":"Antoniou, K. M. et al. ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG). Ann. Rheum. Dis. 85, 22\u201360 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu, G. et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 209, 137\u2013152 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1416_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.rdc.2022.04.001","volume":"48","author":"SR Johnson","year":"2022","unstructured":"Johnson, S. R., Turner, A. S. & Goodman, S. M. How the American College of Rheumatology develops guidelines. Rheum. Dis. Clin. North. Am. 48, 579\u2013588 (2022).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1416_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083867","volume":"389","author":"G Guyatt","year":"2025","unstructured":"Guyatt, G. et al. Core GRADE 7: principles for moving from evidence to recommendations and decisions. BMJ 389, e083867 (2025).","journal-title":"BMJ"},{"key":"1416_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620\u2013628 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327\u20131339 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR11","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton, C. P. et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55, 1906\u20131910 (2016).","journal-title":"Rheumatology"},{"key":"1416_CR12","unstructured":"Howick, J. et al. The 2011 Oxford CEBM Levels of Evidence: Introductory Document. Oxford Centre for Evidence-Based Medicine https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence (2011)."},{"key":"1416_CR13","unstructured":"EULAR SOPs Standard Operating Procedures for Task Forces. EULAR https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/1370\/8af66f37-0fd2-4b47-8f4d-b5e6550e2541\/1292 (2025)."},{"key":"1416_CR14","unstructured":"Creating Clinical Guidelines: British Society for Rheumatology Protocol. British Society for Rheumatology https:\/\/www.rheumatology.org.uk\/Portals\/0\/Documents\/Guidelines\/BSRGuidelinesProtocol_Guidance_v6.0_FINAL_270126.pdf?ver=h7nsbAhrsLajgtDBJZvRfA%3D%3D (2025)."},{"key":"1416_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkad022","volume":"7","author":"CP Denton","year":"2023","unstructured":"Denton, C. P. et al. Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatol. Adv. Pract. 7, rkad022 (2023).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1416_CR16","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1093\/rheumatology\/keaf249","volume":"64","author":"CE Pain","year":"2025","unstructured":"Pain, C. E. et al. Evaluating the relevance of the 2024 BSR systemic sclerosis guideline for juvenile systemic sclerosis. Rheumatology 64, 5179\u20135181 (2025).","journal-title":"Rheumatology"},{"key":"1416_CR17","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","volume":"3","author":"S Bellando-Randone","year":"2021","unstructured":"Bellando-Randone, S. et al. Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol. 3, e834\u2013e843 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1416_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","volume":"72","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova, S. I. et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 72, 465\u2013476 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1416_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66, 1625\u20131635 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1416_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1513\/AnnalsATS.202309-760CME","volume":"21","author":"T Hossain","year":"2024","unstructured":"Hossain, T. et al. Summary for clinicians: clinical practice guideline for the treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. Ann. Am. Thorac. Soc. 21, 12\u201316 (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"1416_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/acr.25346","volume":"76","author":"RD Mirza","year":"2024","unstructured":"Mirza, R. D. et al. Assessing patient values and preferences to inform the 2023 American College of Rheumatology\/American College of Chest Physicians Interstitial Lung Disease Guidelines. Arthritis Care Res. 76, 1083\u20131089 (2024).","journal-title":"Arthritis Care Res."},{"key":"1416_CR22","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962\u20133970 (2006).","journal-title":"Arthritis Rheum."},{"key":"1416_CR23","first-page":"7","volume":"58","author":"S Kundu","year":"2016","unstructured":"Kundu, S. et al. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: an open-label study. Indian J. Chest Dis. Allied Sci. 58, 7\u201310 (2016).","journal-title":"Indian J. Chest Dis. Allied Sci."},{"key":"1416_CR24","first-page":"S85","volume":"32","author":"S Adler","year":"2014","unstructured":"Adler, S. et al. Use of immunosuppressants in SSc patients with interstitial lung disease \u2014 results of the deSScipher project of the EUSTAR group. Clin. Exp. Rheumatol. 32, S85\u2013S86 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1416_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10067-004-0906-7","volume":"23","author":"K Dheda","year":"2004","unstructured":"Dheda, K., Lalloo, U. G., Cassim, B. & Mody, G. M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin. Rheumatol. 23, 306\u2013309 (2004).","journal-title":"Clin. Rheumatol."},{"key":"1416_CR26","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata, S. et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 3, e489\u2013e497 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1416_CR27","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","volume":"4","author":"S Ebata","year":"2022","unstructured":"Ebata, S. et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 4, e546\u2013e555 (2022).","journal-title":"Lancet Rheumatol."},{"key":"1416_CR28","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630\u20132640 (2016).","journal-title":"Lancet"},{"key":"1416_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8, 963\u2013974 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1416_CR30","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1416_CR31","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655\u20132666 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1416_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708\u2013719 (2016).","journal-title":"Lancet Respir. Med."},{"key":"1416_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher, T. M. et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir. Med. 11, 45\u201354 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1416_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002163","volume":"11","author":"F Lombardi","year":"2024","unstructured":"Lombardi, F. et al. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis. BMJ Open. Respir. Res. 11, e002163 (2024).","journal-title":"BMJ Open. Respir. Res."},{"key":"1416_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland, K. B. et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir. Med. 9, 96\u2013106 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1416_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","volume":"81","author":"MO Becker","year":"2022","unstructured":"Becker, M. O. et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann. Rheum. Dis. 81, 507\u2013515 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR37","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1136\/annrheumdis-2015-208121","volume":"75","author":"M Matucci-Cerinic","year":"2016","unstructured":"Matucci-Cerinic, M. et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann. Rheum. Dis. 75, 1770\u20131776 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 70, 32\u201338 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR39","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla, E. et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann. Rheum. Dis. 75, 1009\u20131015 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/23971983251340559","volume":"10","author":"N Maltez","year":"2025","unstructured":"Maltez, N. et al. Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: results from the World Scleroderma Foundation Ad Hoc Committee. J. Scleroderma Relat. Disord. 10, 23971983251340559 (2025).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1416_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/23971983251339821","volume":"10","author":"C Campochiaro","year":"2025","unstructured":"Campochiaro, C. et al. Recommendations for the local management of digital ulcers in systemic sclerosis: a report from the World Scleroderma Foundation (WSF) \u2018Ad hoc committee\u02bc. J. Scleroderma Relat. Disord. 10, 276\u2013284 (2025).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1416_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12016-022-08945-x","volume":"64","author":"A Cole","year":"2023","unstructured":"Cole, A., Ong, V. H. & Denton, C. P. Renal Disease and Systemic Sclerosis: an update on scleroderma renal crisis. Clin. Rev. Allergy Immunol. 64, 378\u2013391 (2023).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1416_CR43","volume":"35","author":"A Villa","year":"2026","unstructured":"Villa, A. et al. Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons. Eur. Respir. Rev. 35, 250137 (2026).","journal-title":"Eur. Respir. Rev."},{"key":"1416_CR44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin, K. M. et al. Treatment algorithm for pulmonary arterial hypertension. Eur. Respir. J. 64, 2401325 (2024).","journal-title":"Eur. Respir. J."},{"key":"1416_CR45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert, M. et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 61, 2200879 (2023).","journal-title":"Eur. Respir. J."},{"key":"1416_CR46","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478\u20131490 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1416_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70131","volume":"7","author":"C Sieiro Santos","year":"2025","unstructured":"Sieiro Santos, C. Autologous hematopoietic stem cell transplantation in systemic sclerosis: current evidence and future directions. ACR Open Rheumatol. 7, e70131 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"1416_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70004","volume":"7","author":"B White","year":"2025","unstructured":"White, B. et al. Comparative efficacy of immunosuppressive therapies in the treatment of diffuse cutaneous systemic sclerosis. ACR Open Rheumatol. 7, e70004 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"1416_CR49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/ard-2023-224416","volume":"83","author":"I Parodis","year":"2024","unstructured":"Parodis, I. et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann. Rheum. Dis. 83, 720\u2013729 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1416_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2026.102139","volume":"40","author":"G Convey","year":"2026","unstructured":"Convey, G., Kuwana, M. & Nikpour, M. Cellular therapies in systemic sclerosis: immunopathogenesis-informed precision targeting with CAR-T and CAR-NK approaches. Best Pract. Res. Clin. Rheumatol. 40, 102139 (2026).","journal-title":"Best Pract. Res. Clin. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01416-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:01:53Z","timestamp":1790078513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01416-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1416"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01416-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"16 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.D.G. has received speaker\u2019s bureau fees from AstraZeneca and Janssen; consulting fees from AstraZeneca, Boehringer Ingelheim, Capella, Chemomab, Janssen and Mitsubishi Tanabe; and grant\/research support from AbbVie, AstraZeneca, Boehringer Ingelheim, Capella, Chemomab, Kymab, Janssen and Mitsubishi Tanabe. Y.A. has a consultancy relationship with AbbVie, Amgen, Argenx, AstraZeneca, Boehringer Ingelheim, BMS, ByImmunity, Genentech\/Roche, GSK, Horizon, Medsenic, Novartis, Prometheus, Topadur, Quell and Zura Bio; and has research funds from Alpine ImmunoSciences, Corbus, Merck Serono and Medsenic. O.D. has acted as a consultant for and\/or has received research funding from and\/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the past 3 calendar years (4P-Pharma, AbbVie, Acepodia, Aera, Amgen, AnaMar, Anaveon, Argenx, AstraZeneca, Avalyn, Boehringer Ingelheim, Bristol Myers Squibb, Calluna, Cantargia, CSL Behring, EMD Serono, Galderma, Fimmcyte, Galapagos, Gossamer, Hemetron, Innovaderm, Kali, Lilly, Mediar, Merck Sharp & Dohme, Nkarta, Novartis, Oorja Bio, Orion, Pliant, Prometheus, Quell, Scleroderma Research Foundation, Skyhawk, Tandem, Topadur, UCB and Umlaut.bio); has a patent that has been issued for his research (\u201cmir-29 for the treatment of systemic sclerosis\u201d (US8247389, EP2331143)); is a co-founder of CITUS AG; has received consultancy fees from Boehringer Ingelheim, AstraZeneca, Argenx, Topadur and Horizon; and has received grant\/research support from Alpine, Corvus and Merck Serono. A.M.H.-V. has received payment or honoraria for lectures, presentations, or speakers\u2019 bureau fees from Boehringer Ingelheim, Merck Sharp & Dohme, and Novartis; has received consultancy fees from AbbVie, Calluna Pharma, Argenx, Janssen, AstraZeneca, Merck Sharp & Dohme, Avalyn, Pliant Therapeutics, Bristol Myers Squibb, UCB, Boehringer Ingelheim and Werfen; has participated on data-safety-monitoring boards or advisory boards for GlaxoSmithKline; received grant\/research support from AstraZeneca, Boehringer Ingelheim, and Janssen; has received support for attending meetings and\/or travel from Boehringer Ingelheim; and serves as a EULAR study group leader on the lung in rheumatic and musculoskeletal diseases. S.J. is supported by the American College of Rheumatology. D.K. has been a consultant to AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Cabaletta Bio, Liquidia, Merck, Mitsubishi Tanabe, Novartis, Pharmosa and Zura Bio; and has received grants from Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim and Pfizer. V.H.O. reports consultancy or speaker fees from Boehringer Ingelheim and Zura Bio. E.A.R. reports advisory board and lecture fees from Boehringer Ingelheim and Roche and lecture fees from Mundipharma, paid to her institution. E.R.V. reports research grant support from Boehringer Ingelheim, Kadmon, Horizon, GSK, Prometheus, aTyr Pharm and AstraZeneca; consulting fees from Boehringer Ingelheim, GSK and AbbVie; and speaker fees from Boehringer Ingelheim. C.P.D. reports consultancy or speaker fees from Johnson & Johnson, GlaxoSmithKline, AbbVie, Sanofi, Boehringer Ingelheim, Roche, Lilly, Novartis, Zura Bio, Argenx, Quell, Cabaletta and Bristol Myers Squibb.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}